The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury
Abstract
Idiosyncratic drug induced liver injury (DILI) is an infrequent but important cause of liver disease. Newly identified causes of DILI include the COVID vaccines, turmeric, green tea extract, and immune checkpoint inhibitors. DILI is largely a clinical diagnosis of exclusion that requires evaluation for more common causes of liver injury and a compatible temporal association with the suspect drug. Recent progress in DILI causality assessment includes the development of the semi-automated Revised Electronic Causality Assessment Method (RECAM) instrument. In addition, a number of drug specific HLA associations have been identified which can help with the confirmation or exclusion of DILI in individual patients. Various prognostic models can help identify the 5 to 10% of patients at highest risk of death. Following suspect drug cessation, 80% of DILI patients will fully recover while 10 to 15% have persistently abnormal labs at 6 months of follow-up. Hospitalized DILI patients with an elevated INR or mental status changes should be considered for N-acetylcysteine therapy and urgent liver transplant evaluation. Selected patients with moderate to severe DRESS or autoimmune features on liver biopsy may benefit from short-term corticosteroids. However, prospective studies are needed to determine the optimal patients and dose and duration of steroids to use. LiverTox is a comprehensive, freely accessible website with important information regarding the hepatotoxicity profile of over 1000 approved medications and 60 HDS products. Ongoing "omics" studies will hopefully lead to additional insight into DILI pathogenesis, improved diagnostic and prognostic biomarkers and mechanism-based treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hospitalized patients with DILI with coagulopathy and hepatic encephalopathy should promptly be considered for LT evaluation as their likelihood of spontaneous recovery is <30%.[26,28]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Self-citationLiver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Self-citationHigh-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids
Shinozawa, T., Kimura, M., Cai, Y., Saiki, N., Yoneyama, Y., Ouchi, R., Koike, H., Maezawa, M., Zhang, R.-R., Dunn, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.002 · Cited by 378
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Self-citationA revised electronic version of RUCAM for the diagnosis of DILI
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., Gonzalez‐Jimenez, A., Yang, Q., Gu, J., Andrade, R. J., et al. (2022) · Hepatology · doi:10.1002/hep.32327 · Cited by 160
Self-citationBjörnsson, H. K., Björnsson, E. S., Avula, B., Khan, I. A., Jonasson, J. G., Ghabril, M., Hayashi, P. H., & Navarro, V. (2020) · Liver International · doi:10.1111/liv.14393 · Cited by 125
Self-citationBessone, F., García-Cortés, M., Medina-Caliz, I., Hernandez, N., Parana, R., Mendizabal, M., Schinoni, M. I., Ridruejo, E., Nunes, V., Peralta, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.011 · Cited by 60
Self-citationNavarro, V., Avula, B., Khan, I., Verma, M., Seeff, L., Serrano, J., Stolz, A., Fontana, R., & Ahmad, J. (2019) · Hepatology Communications · doi:10.1002/hep4.1346 · Cited by 52
Self-citation
Research works printed but not linked: 62
- Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
- DiPaola, 2019, Antimicrobials and antiepileptics are the leading causes of idiosyncratic drug-induced liver injury in American children, J Pediatr Gastroenterol Nutr, 69, 152, 10.1097/MPG.0000000000002383 · DOI · Paper page
- George, 2018, Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury, Regul Toxicol Pharmacol, 94, 101, 10.1016/j.yrtph.2018.01.018 · DOI · Paper page
- Hoofnagle, 2021, HLA-B ∗ 35:01 and green-tea induced liver injury, Hepatology, 73, 2484, 10.1002/hep.31538 · DOI · Paper page
- Vuppalanchi R, Bonkovsky HL, Ahmad J, et al. Garcinia cambogia either alone or in combination with green tea, causes moderate to severe liver injury. Clin Gastroenterol Hepatol. Published online June 20, 2022. https://doi.org/10.1016/j.cgh.2021.08.015. · DOI
- Halegoua-DeMarzio, 2022, Liver injury associated with turmeric, a growing problem: ten cases from the Drug-Induced Liver Injury Network, Am J Med December
- Stolz, 2019, Severe and protracted cholestasis in 44 young mean taking bodybuilding supplements: assessment of genetic, clinical, and chemical risk factors, Aliment Pharmacol Ther, 49, 1195, 10.1111/apt.15211 · DOI
- Chalasani, 2022, Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study, J Hepatol, 76, 832, 10.1016/j.jhep.2021.12.013 · DOI
- Björnsson, 2022, Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment, J Hepatol, 76, 86, 10.1016/j.jhep.2021.08.024 · DOI · Paper page
- Miller, 2020, Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors, Am J Gastroenterol, 115, 261, 10.14309/ajg.0000000000000398 · DOI
- Yoshikawa, 2021, A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, Clin J Gastroenterol, 14, 283, 10.1007/s12328-020-01287-1 · DOI
- Björnsson, 2022, Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports, Hepatol Commun, 6, 1895, 10.1002/hep4.1959 · DOI · Paper page
- Kukkarni, 2022, Tinospora cofdifolia (Giloy)–induced liver injury during the COVID-19 pandemic: multicenter nationwide study from India, Hepatol Commun, 6, 1289, 10.1002/hep4.1904 · DOI
- Chow, 2022, Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature, Dig Dis Sci, 67, 4574, 10.1007/s10620-022-07504-w · DOI
- Efe, 2022, Liver injury after SARS-CoV-2 vaccination: features of immune mediated hepatitis, role of corticosteroid therapy, and outcome, Hepatology, 76, 1576, 10.1002/hep.32572 · DOI · Paper page
- Ahmad, 2021, Liver injury associated with a popular opioid-like product: experience from the US DILIN and a review of the literature, Drug Alcohol Depend, 218, 10.1016/j.drugalcdep.2020.108426 · DOI · Paper page
- Fontana, 2009, DILIN prospective study: rationale, design, and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Fontana, 2022, Incidence of hepatitis E infection in American patients with suspected drug-induced liver injury is low and declining: the DILIN Prospective study, Am J Gastroenterol, 117, 1462, 10.14309/ajg.0000000000001869 · DOI
- Ahmad, 2019, Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury, Dig Dis Sci, 64, 2645, 10.1007/s10620-019-05591-w · DOI
- Alpers, 2023, Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease: an analysis of pivotal clinical trials, Am J Kidney Dis, 81, 281, 10.1053/j.ajkd.2022.08.012 · DOI
- Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury. Systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
- Ahmad, 2022, Value of liver biopsy in the diagnosis of DILI, J Hepatol, 76, 1070, 10.1016/j.jhep.2021.12.043 · DOI · Paper page
- Bjornsson, 2016, Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports, Hepatology, 63, 59, 10.1002/hep.28323 · DOI · Paper page
- Bjornsson, 2015, Discrepancies in liver disease labelling in the package inserts of commonly prescribed medications, Gastroenterology, 149, 269, 10.1053/j.gastro.2014.12.007 · DOI · Paper page
- Wu, 2021, A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labelling reveals discrepancies, Drug Discov Today, 27, 337, 10.1016/j.drudis.2021.09.009 · DOI · Paper page
- Danan, 2016, RUCAM in drug and herb induced liver injury: the update, Int J Mol Sci, 27, 14
- Devarbhavi, 2022, Comparison of Roussel-Uclaf causality assessment method (RUCAM) versus revised electronic causality assessment method (RECAM): analysis of 100 cases from an Indian Registry, Hepatology, 76
- Li, 2019, HLA-B ∗ 35:01 allele is a potential biomarker for predicting polygonum multiforum induced liver injury in humans, Hepatology, 70, 346, 10.1002/hep.30660 · DOI · Paper page
- Cirulli, 2019, A missense variant in PTPN22 is a risk factor for drug-induced liver injury, Gastroenterology, 156, 1707, 10.1053/j.gastro.2019.01.034 · DOI · Paper page
- Church, 2019, Candidate biomarkers for the diagnosis and prognosis of DILI: an international collaborative effort, Hepatology, 69, 767, 10.1002/hep.29802 · DOI · Paper page
- Wagner, 2021, Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a phase II trial, Biomark Med, 15, 1389, 10.2217/bmm-2021-0222 · DOI
- Llewellyn, 2021, Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans, Toxicol Sci, 181, 23, 10.1093/toxsci/kfab003 · DOI
- Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- Andrade, 2005, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- Hayashi, 2017, Death and liver transplantation within 2 years of onset of drug-induced liver injury, Hepatology, 66, 1275, 10.1002/hep.29283 · DOI · Paper page
- Fontana, 2014, DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
- Chalasani, 2017, Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians, Am J Gastroenterol, 112, 1382, 10.1038/ajg.2017.215 · DOI · Paper page
- Stephens, 2021, Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry, J Hepatol, 75, 86, 10.1016/j.jhep.2021.01.029 · DOI · Paper page
- Ghabril, 2019, Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected DILI, Gastroenterology, 157, 1245, 10.1053/j.gastro.2019.07.006 · DOI · Paper page
- Robles-Diaz, 2014, Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with DILI, Gastroenterology, 147, 109, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
- Lewis, 2021, Effects of bardoxolone methyl on hepatic enzymes in patients with type 2 diabetes mellitus and stage 4 CKD, Clin Transl Sci, 14, 299, 10.1111/cts.12868 · DOI
- Fontana, 2015, Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug-induced liver injury, Am J Gastroenterol, 110, 1450, 10.1038/ajg.2015.283 · DOI · Paper page
- Medina-Caliz, 2016, Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J Hepatol, 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
- Björnsson, 2022, Long-term sequelae of drug-induced liver injury, J Hepatol, 76, 435, 10.1016/j.jhep.2021.10.011 · DOI
- Björnsson, 2022, Role of corticosteroids in drug-induced liver injury: a systematic review, Front Pharmacol, 13, 10.3389/fphar.2022.820724 · DOI · Paper page
- Karkhanis, 2014, Steroid use in ALF, Hepatology, 59, 612, 10.1002/hep.26678 · DOI · Paper page
- Tsung, 2019, Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy, Aliment Pharmacol Ther, 50, 800, 10.1111/apt.15413 · DOI · Paper page
- Swanson LA, Kassab I, Tsung I, et al. Liver injuring during durvulumab-based immunotherapy is associated with poorer patient survival: a retrospective analysis. Front Oncol. Published online October 24, 2022. https://doi.org/10.3389/fonc.2022.984940 · DOI · Paper page
- Bessone, 2022, Checkpoint inhibitor-induced hepatoxicity: role of liver biopsy and management approach, World J Hepatol, 14, 1269, 10.4254/wjh.v14.i7.1269 · DOI
- Schneider, 2021, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update, J Clin Oncol, 39, 4073, 10.1200/JCO.21.01440 · DOI · Paper page
- Fecher, 2022, The role of tissue biopsy in the management of immune checkpoint inhibitor toxicity, J Natl Compr Canc Netw, 20, 417, 10.6004/jnccn.2022.7011 · DOI
- Lee, 2009, Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 · DOI · Paper page
- Moosa, 2021, A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury, Clin Infect Dis, 73, e3377, 10.1093/cid/ciaa1255 · DOI · Paper page
- Squires, 2013, Pediatric Acute Liver Failure Study Group. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial, Hepatology, 57, 1542, 10.1002/hep.26001 · DOI · Paper page
- Robles-Diaz, 2021, Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review, Front Pharmacol, 12, 10.3389/fphar.2021.744488 · DOI · Paper page
- Perrott, 2010, L-carnitine for acute valproic acid overdose: a systematic review of published cases, Ann Pharmacother, 44, 1287, 10.1345/aph.1P135 · DOI · Paper page
- Devarbhavi, 2022, Leflunomide induced liver injury: differences in characteristics and outcomes in Indian and US registries, Liver Int, 42, 1323, 10.1111/liv.15189 · DOI
- Richardson, 2016, Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure, Blood, 127, 1656, 10.1182/blood-2015-10-676924 · DOI · Paper page
- Benic, 2022, Novel therapies for the treatment of drug-induced liver injury: a systematic review, Front Pharmacol, 12, 10.3389/fphar.2021.785790 · DOI
- Stine, 2016, Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review, Expert Rev Gastroenterol Hepatol, 10, 517, 10.1586/17474124.2016.1127756 · DOI · Paper page
- Niu, 2021, Prevention and management of idiosyncratic drug-induced liver injury: systematic review and meta-analysis of randomized clinical trials, Pharmacol Res, 164, 10.1016/j.phrs.2020.105404 · DOI · Paper page
- Rao, 2022, Secular trends in severe idiosyncratic drug-induced liver injury in North America: an update from the ALFSG Registry, Am J Gastroenterol, 117, 617, 10.14309/ajg.0000000000001655 · DOI · Paper page
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
Drug-induced liver injury: Diagnosis, management and the role of liver transplantation
Ozturk, N. B., Uskudar, E., Toruner, M. D., Simsek, C., & Gurakar, A. (2025) · Hepatology Forum · doi:10.14744/hf.2024.2024.0003 · Cited by 9
Metadata
- Authors
- Fontana, R. J., Bjornsson, E. S., Reddy, R., & Andrade, R. J.
- ORCID
- Fontana, Robert J.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 21
- Issue
- 8
- Pages
- 2088-2099
- ISSN
- 1542-3565
- Cited by
- 66
- References
- 10
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Novo Nordisk
- Spark Therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. https://app.cochat.ai/papers/10.1016/j.cgh.2022.12.040
- The paper
- Fontana, R. J., Bjornsson, E. S., Reddy, R., & Andrade, R. J. (2023). The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.12.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.